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Nevena Cvjetkovic, B.S. 
Nonsyndromic cleft lip with or without cleft palate (NSCLP) is a common birth 
defect with a multifactorial etiology.  Despite decades of research, the genetic underpinnings 
of NSCLP still remain largely unexplained.  A genome wide association study (GWAS) of a 
large NSCLP African American family with seven affected individuals across three 
generations found evidence for linkage at 8q21.3-24.12 (LOD = 2.98).  This region 
contained three biologically relevant candidate genes: Frizzled-6 (FZD6) (LOD = 2.8), 
Matrilin-2 (MATN2) (LOD = 2.3), and Solute Carrier Family 25, Member 32 (SLC26A32) 
(LOD = 1.6).   Sequencing of the coding regions and the 5’ and 3’ UTRs of these genes in 
two affected family members identified a rare intronic variant, rs138557689 (c.-
153+432A>C), in FZD6.  The rs138557689/C allele segregated with the NSCLP phenotype; 
in silico analysis predicted and EMSA analysis showed that the 138557689/C allele creates 
new DNA binding sites.  FZD6 is part of the WNT pathway, which is involved in 
craniofacial development, including midface development and upper lip fusion.  Our novel 
findings suggest that an alteration in FZD6 gene regulation may perturb this tightly 
controlled biological pathway and in turn contribute to the development of NSCLP in this 
family.  Studies are underway to further define how the rs138557689/C variant affects 
expression of FZD6. 
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INTRODUCTION 
Isolated or nonsyndromic cleft lip with or without cleft palate (NSCLP) is the fourth 
most common  birth defect affecting more than 4,000 births each year in the United States  
[1,2,3].  Despite the improvements in treatment, NSCLP has considerable medical and 
financial implications for the affected individuals and their families, and the effects on 
speech, hearing, and appearance can lead to adverse psychosocial and psychiatric outcomes 
[4,5,6].  Individuals with NSCLP require multidisciplinary team care through adulthood and 
continue to demonstrate increased morbidity and mortality rates compared to the general 
population [7,8].  
Cleft lip and palate has been recognized and documented throughout history.  First 
evidence of clefting was noted in an Egyptian mummy dating from 2400 to 1300 BC [9].  A 
2000-year-old statue of a Columbian king, a 2000-year old African mask, a Ming dynasty 
painting, and a 20
th
 century Russian painting all depicted orofacial clefts [9].  What appears 
to be the first documented treatment of cleft lip and palate was performed in 390AD by a 
Chinese physician [10].   
Many different explanations for causation of cleft lip and palate have evolved among 
the various cultures and populations in the world.   Causes are often attributed to maternal 
impressions or supernatural events [11].  The term “hare-lip” to describe cleft lip originated 
from beliefs that clefting results from eating or looking at a rabbit [12,13].  A prevailing 
belief in many cultures is that a child will be born with a birth defect, including cleft lip and 
palate, if a woman pities or makes fun of an affected individual while pregnant [13,14,15].  
Supernatural causes, such as the effect of the moon (lunar eclipse), are alleged causes of 
cleft lip and palate in Mexican folklore and among Hispanic populations [14,15,16], while 
populations in India and Nigeria ascribed the cleft to “God's will”, evil and ancestral spirits, 
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or sins committed in past lives [17,18].  Thesis work of Fogh-Andersen in 1942 was the first 
to widely recognize the hereditary component of CLP [19]. 
Despite the fact that NSCLP has been part of human life for many centuries, and the 
fact that many beliefs for the causation of this birth defect exist, the etiology of NSCLP is 
still largely unknown.  Continual research in this area is needed to help elucidate the 
underlying etiologies of this common birth defect in order to improve genetic counseling for 
recurrence, diagnosis, prevention, and treatment, as well as to improve our understanding of 
the development of clefts.  
 
Classification of Clefts 
Orofacial clefts are divided into two groups based on developmental origin:  anterior 
and posterior clefts [20].  Anterior cleft anomalies include cleft lip (CL) only, or cleft lip and 
primary palate (CLP) [20].  Anterior clefts can extend through the lip and alveolar part of 
the maxilla (primary or hard palate) to the incisive fossa [20].   Posterior cleft anomalies, 
which include clefts of the secondary or soft palate, present as cleft palate only (CPO) [9,20]  
Posterior clefts extend through the soft and hard sections of the palate to the incisive fossa 
[20]. 
Clefts can further be divided into syndromic or nonsyndromic.  Syndromic clefts are 
distinguished by the presence of other congenital malformations and may be associated with 
specific genes, chromosomal abnormalities, or maternal teratogenic exposures [21].  
Approximately 30% of CLP and 50% of CPO are associated with other syndromes or 
anomalies, and there are currently over 400 different conditions listed on Online Mendelian 
Inheritance of Man in which clefts occur (http://www.ncbi.nlm.nih.gov/omim) [21].  Table 1 
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is an abbreviated list of syndromes which have CLP or CPO as a phenotypic finding and the 
genes associated with them.  The remaining 70% of cases of CLP and 50% of cases of CPO 
are isolated, and therefore are referred to as nonsyndromic [21].  Nonsyndromic CLP 
(NSCLP) is the focus of this study.    
 
 
A cleft can be unilateral, occurring on one side of the face, or bilateral, occurring on 
both sides of the face.  Unilateral clefts account for 90% of CLP (~60% of which occur on 
the left side) while bilateral clefts account for the remaining 10% [21].   
 Recurrence of syndromic CLP depends on the underlying genetic condition, while 
recurrence risk for NSCLP depends on several factors including number of affected 
individuals in family, relation of affected family member, and laterality of the cleft [22].  
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The empirical recurrence risk for siblings is 2-3% in a case of unilateral CLP and 3-5% in 
the case of bilateral CLP [22].   
 
Birth Prevalence  
Cleft lip with or without palate is estimated to occur in approximately 1/700 to 
1/1000 births but the prevalence of clefts varies by ethnicity [21,23].  The frequency of 
NSCLP appears to be highest among Native Americans (~3.6/1000 births) followed by 
Japanese (~2.1/1000 births) and Chinese (~1.7/1000 births) populations, and appears to be 
the lowest among African derived populations (~0.3/1000 births) [9].   In Texas, the 
prevalence of NSCLP is 0.67/1000 for Non-Hispanic Whites, 0.63/1000 for US-born 
Hispanics, 0.65/1000 for non-US born Hispanics, and 0.40/1000 for African Americans [1].   
Birth prevalence of NSCLP also varies by gender with a 2:1 male to female ratio 
[24].   An association between NSCLP and socioeconomic status is implicated by studies 
which show groups from rural, lower socioeconomic areas having a higher birth prevalence 
of NSCLP compared to ethnically similar groups within higher socioeconomic status [21].   
The birth prevalence of isolated CPO is approximately 1/2000 births and does not 
appear to differ much between various ethnicities [21].   In contrast to NSCLP, there is a 
female predominance of isolated CPO with a 3:2 female to male ratio [25].  
 
Normal Development of the lip and palate 
Understanding of normal development of the upper lip, primary, and secondary 
palates is important to help explain the reason for the altered development seen in CLP.  
Normal craniofacial development is a complex process directed by intricate pathways 
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important for cell induction, differentiation, proliferation, migration, patterning, and 
apoptosis [8,26].  Molecular pathways, including the Bmp, Fgf, Shh, and Wnt pathways, 
coordinate craniofacial development through both synergistic and antagonistic signaling 
[26].  Numerous genes, which code for growth factors, transcription factors, cell adhesion 
molecules, and signaling molecules, strictly regulate the development of the face 
[19,27,28,29,30].  Theoretically, perturbations within any of these genes and pathways could 
alter craniofacial morphogenesis and result in clefting.     
 The human face begins developing in the 4th week of embryogenesis [28].  Neural 
crest cells (NCCs), which are the major source of connective tissue components, migrate 
from the neural folds and combine with the core mesoderm and the epithelia to establish five 
facial primordia [20,26].  As depicted in Fig. 1a, the primodia consist of a single frontonasal 
prominence, two mandibular and two maxillary prominences, all of which surround the 
primitive oral cavity [8,28].  Ectodermal thickenings form nasal placodes and results in the 
formation of nasal pits by the end of week 4.  The nasal pits further divide the frontonasal 
prominence into two horseshoe-shaped medial and lateral nasal processes (Fig. 1b) [8,26].     
Rapid growth of the underlying mesenchyme of the facial primordia causes the 
medial nasal prominences to merge with each other and with the maxillary and lateral nasal 
prominences between the 7
th
 to 10
th
 week of embryogenesis [20].  The contact epithelia 
between the prominences are broken up by cell apoptosis to give rise to the intermaxillary 
segment from which the philtrum of the upper lip, the premaxillary part of the maxilla and 
the primary palate are formed (Fig. 1c) [20,26].   
 The secondary palate, which comprises majority of the soft palate, except for the 
anterior portion that holds the incisor teeth, has a different developmental origin [20].  
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Palatal shelves, which originate from the maxillary processes, appear in the 6
th
 week of 
development and grow downward, vertical to the sides of the developing tongue (Fig. 1d)  
[8,9].  The palatal shelves then elevate to a horizontal position above the tongue (Fig. 1e), 
and fuse together (Fig. 1f) [8,20].  This is thought to occur earlier in females then in males 
[9].  Additionally, the two palatal shelves merge with the primary palate and the nasal 
septum dividing the oral from the nasal cavity [8].  This process is complete by the end of 
the 10
th
 week [9,20]. 
 
 
Development of Cleft Lip and Palate 
Cleft lip and palate can result when any of the multifaceted factors involved in 
normal facial morphogenesis are disrupted or altered.  These may include failure of fusion of 
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the processes that form the face, distortions in epithelial movement, deficiency in epithelial 
and mesenchymal transformation (EMT), or failure in apoptosis [26]. 
Deficiency of mesenchyme in the maxillary prominence(s) and the median palatal 
process leads to anterior clefts [20].  Failure of one maxillary prominence to unite with the 
two merged medial nasal prominences results in unilateral cleft of the upper lip, while 
failure of both maxillary prominences to unite with the merged medial nasal prominences 
results in bilateral cleft of the upper lip [9,20].   
Defective development of the secondary palate leads to posterior palatal clefts [20].  
This is mainly due to the failure of mesenchymal masses in the lateral palatal processes to 
meet and fuse with each other and the nasal septum [9,20].      
 
Treatment of NSCLP 
Treatment of a patient with CLP requires a multidisciplinary approach which 
includes craniofacial and maxillofacial surgery, dentistry and orthodontic, audiology, 
otolaryngology, speech and language, nursing, pediatrics, genetics, and social services [31].  
Many different surgical protocols exist to repair CLP and treat ensuing complications [21].  
Currently, however, there is not an internationally accepted protocol for CLP repair [32].   
Surgical repair of the CLP usually occurs within the first six months of life, the 
general rule being to perform surgical repair when the child is approximately 10 weeks of 
age, weighs at least 10 lb, and has achieved serum hemoglobin of 10 mg/ml [33].   There are 
various techniques of CLP repair which have been refined throughout time and some of 
these include LeMesurier (1955), Tennison (1952), Millard (1950), Skoog (1969), Randall 
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(1990) and Brauer (1985).  The choice of technique, however, most often depends on 
surgeon preference and severity of cleft [21]. 
 
Etiology of NSCLP 
  NSCLP does not follow a traditional Mendelian pattern of inheritance but is believed 
to result from a combination of several genetic variants which act in an additive fashion and 
interact with the environment to produce the phenotype [21].  NSCLP is therefore 
considered to be a multifactorial disorder that results from the interaction of both genetic 
and environmental factors [21].  Genetic evidence for NSCLP comes from multiple studies.  
These studies show that NSCLP aggregates in families, that there is a family history for 
clefting in 24-33% of NSCLP patients with a 10 to 32-fold increase in recurrence risk to first 
degree relatives, that the heritability of NSCLP in the NHW population is approximately 
76%, and that the rate of concordance is higher in monozygotic (25-40%) than dizygotic (3-
6%) twins [9,21,34,35,36,37,38,39].  Various environmental factors have also been 
associated with an increased risk for NSCLP including smoking, alcohol, diet, infections, 
fever, drugs, and teratogenic agents during early pregnancy [21,40,41,42,43].    
Only a handful of genes associated with NSCLP have been identified to date and 
these comprise approximately 20% of the genetic causes of NSCLP [44].   Interferon 
regulator factor 6 (IRF6) is one of the genes that has shown an association with NSCLP in 
multiple populations [45,46,47,48,49,50].  Mutations in IRF6 are also known to cause van 
der Woude syndrome [51].  Various other genes, which include growth factors (TGFα, 
TGFβ), transcription factors (MSX1, TBX22), genes involved in xenobiotics (CYP1A1, 
GSTM1, NAT2), and other genes (RARA, MTHFR, CRISPLD2), have also been associated 
9 
 
with NSCLP [52,53,54,55,56,57,58,59,60,61].  The constant identification of novel genes 
for the pathogenesis of NSCLP across various populations highlights the genetic 
heterogeneity of this complex birth defect.     
 
Gene identification in NSCLP 
Multiple genetic approaches have been used to identify the genes and pathways 
contributing to NSCLP.  These approaches include assessment of mouse models, linkage 
analysis using large multiplex families and affected relative pairs, association studies using 
family-based or case-control samples, identification of chromosomal anomalies or 
microdeletions in affected cases, and candidate gene studies [62].   
Recently, genome-wide association studies (GWAS) have expanded the research in 
NSCLP and markedly helped in the identification of new candidate genes.  GWAS studies 
use known single nucleotide polymorphisms (SNPs) that cover the genome to identify 
regions that are linked to and/or associated with NSCLP [62].  Identification of candidate 
genes by GWAS permits further analysis of individual genes through direct sequencing [62].   
Sequencing of the candidate genes allows for identification of sequence variants within the 
gene which could potentially contribute to the development of NSCLP [62].  The sequence 
variants can be located within protein coding regions as well as noncoding regions, which 
include promoter/enhancer regions, or introns of the gene [63].  
 
8q21.3-24.12 Chromosomal Region 
A GWAS study performed in 2009 identified a major locus for NSCLP on 
chromosome 8q24 but the region with highest linkage did not contain any protein coding 
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genes [64].  Subsequent GWAS studies confirmed the association with the 8q24 locus and 
identified additional loci including 10q25, 7q22, 20q12, and 1p22 [62].  A smaller GWAS 
study reported by Chiquet et al. evaluated 10 multiplex NSCLP families including one large 
African-American family with 11 affecteds across 3 generations (Fig. 2).  It was performed 
to confirm existing and identify new NSCLP chromosomal regions [65].  The study found 
evidence for linkage on 8q21.3-24.12 (LOD=2.98) [65].  Further evaluation of this region 
using linkage analysis generated a maximum multipoint LOD score of 2.8 for SNPs in 
Frizzled 6 (FZD6), 2.3 in Matrilin-2 (MATN2), and 1.6 in Solute carrier family 25, member 
32 (SLC26A32), prompting further analysis of these three genes and their connection to 
NSCLP. 
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Frizzled-6 and WNT pathway 
Human Frizzled-6 (FZD6) gene maps to chromosome 8q22.3-q23.1 and encodes a 
706 amino-acid seven-pass transmembrane protein with a cystine-rich domain in the N-
terminal extracellular region, two-N linked glycosylation sites, and two cystine residues in 
the second and third extracellular loops [66].   A total of 7 exons, 6 of which are coding, 
comprise the FZD6 gene [66].  FZD6 amino acid sequence is well conserved between mouse 
and human genes with an amino acid identity of 83.3% [66]. 
FZD6 is part of the Frizzled gene family which code for a group of receptors critical 
for initiation of wingless-type (WNT) signaling pathway [67].  The Frizzled receptors share 
conserved features which include a cystine-rich domain in the N-terminal extracellular 
region implicated in the binding of WNT ligands, N-linked glycosylation sites, two cystine 
residues in the second and third extracellular loops, and a Ser/Thr-x-Val motif in the C-
terminus which acts as a binding site for the cytoplasmic protein containing the PDZ domain 
[66,68,69]. 
FZD6 codes for three mRNA isoforms that are detected in both adult and fetal 
tissues [70].   FZD6 was shown to be important for hair patterning in both Drosophila and 
mice as well as mice claw morphogenesis and appears to act within the WNT/PCP (planar 
cell polarity) pathway [71,72,73].  Mutations in FZD6 have been associated with isolated 
autosomal recessive nail dysplasia and open neural tube defects in humans [71,74,75].  
  WNT signaling regulates differentiation and proliferation of a variety of cell types 
during development and is an important regulator of various functions within the cells [76].  
Signaling by the WNT pathway directs cell proliferation, cell polarity, and cell fate 
determination during embryogenesis and homeostasis, regulates multiple developmental 
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processes, and plays a critical role in embryogenesis through both canonical (β-catenin 
dependent) and noncanonical (WNT/PCP and Ca2+/CAMKII) signaling [76,77].   
The canonical/ β-catenin pathway is the best understood.  As depicted in Fig. 3a, 
when a WNT ligand is absent, cytoplasmic β-catenin forms a complex with the scaffolding 
protein Axin, the tumor suppressor adenomatous polyposis coli gene product (APC), 
glycogen syntahse kinase 3B (GSK3B) and casein kinase 1 (CK1), and is phosphorylated by 
CK1 and subsequently by GSK3B [67].  Phosphorylated β-catenin is then recognized by the 
E3 ubiquitin ligase (UB), and is targeted for degradation within the proteosome [78].  This 
degradation, in turn, prevents β-catenin from reaching the nucleus, where the WNT target 
genes are repressed by the DNA-bound T cell factor/lymphoid  enyhancer factor (TCF-
TLE)/Groucho and histone deacetylases (HDAC) [67]. 
Transcription of WNT target genes is activated in the presence of WNT ligand.  As 
shown in Fig. 3b, the WNT ligand binds to a receptor complex formed between Frizzled and 
low-density lipoprotein receptor related protein 5 or 6 (LRP5/6).  This complex then recruits 
a scaffolding protein Dishevelled (Dvl) and leads to LRP5/6 phosphorylation and Axin 
recruitment [67,77].  This interrupts Axin-mediated phosphorylation and subsequent 
degradation of β-catenin, and allows β-catenin to build up in the nucleus where it can 
activate  TCF/LEF and initiate transcription of WNT responsive genes [67].  
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In contrast to other Frizzled receptors, FZD6 protein lacks the Ser/Thr-X-Val motif 
at the C-terminal common to other frizzled receptors and has been shown to repress 
canonical WNT signaling through the noncanonical Ca2+/CaMKII pathway by inhibiting 
the TCF/LEF binding activity and down-regulating β-catenin targeted transcription of WNT 
genes [66,70].  Removal of FZD6’s N or C terminal sequences, however, abolishes the 
repressive activity of the protein [70]. 
Mutations in the WNT pathway have been linked to a variety of birth defects, 
cancers, and other diseases [67].  Importantly, WNT signaling has been shown to play a role 
in craniofacial development, including regional specification in the vertebrate face, neural 
crest induction and differentiation, mid-face development and upper lip fusion in mice, and 
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facial morphogenesis in mice [26,79,80,81,82,83,84,85].  Craniofacial abnormalities, 
including orofacial clefts, are found in WNT knockout mice and zebrafish [86,87].  An 
association with individual WNT genes and NSCLP has been found in humans (WNT3, 
WNT3A, WNT5A, WNT7A, WNT8A, WNT9B and WNT11) [87,88,89,90].  Based on this 
information, FZD6 is a strong candidate gene for NSCLP.  Coding mutations or variants in 
the regulatory regions of FZD6 may alter the tightly regulated WNT pathway, and in turn 
contribute to NSCLP.    
 
Matrilin-2 and the extracellular matrix assembly 
Matrilin-2 (MATN2) gene maps to chromosome 8q22.1-q22.3 and encodes a 956 
amino-acid protein whose structure consists of a putative signal peptide, two von 
Willerbrand factor A (vWFA)-like domains parted by ten epidermal growth factor (EGF)-
like domains, a unique segment not seen in other matrilins, and an α-helical coiled-coil (CC) 
domain [91,92,93].   MATN2 has 19 exons and is transcribed from two alternative 
promoters, one of which is an upstream housekeeping-type promoter functional in 
fibroblasts and other cell types, and a downstream TATA-like promoter restricted to only 
embryo fibroblast and certain cell lines [94].   Matrilin-2 protein functions as a part of a 
tightly regulated pathway in the extracellular matrix (ECM) assembly and it is found in a 
wide variety of connective tissue cells, smooth muscle cells, and both the dermis and the 
epidermis in humans [93,95].  Human and mice Matrilin-2 proteins show 86.5% identity 
[93].   
Matrilin-2 belongs to a family of four ECM proteins (matrilin-1, -2, -3, and -4), all of 
which share a structure made of vWFA and EGF domains, and a α-helical CC segment [92].  
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The matrilin genes also share a phase I, U-12-type AT-AC intron that is located in a strictly 
conserved position that separates the two exons for the CC domain [94].  While matrilin-1 
and matrilin-3 are expressed mainly in cartilage and skeletal tissue, matrilin-2 and -4 have 
wider tissue distribution, including some non-skeletal tissues [91].  Matrilins -1, -2, and -3 
can form filamentous networks that can connect to collagen fibers [93].  While Matrilin-2 is 
expressed in the mesoderm and epithelium in mice it is expressed in the dermal side of the 
basement membrane at the dermal-epidermal junction, as well as in keratinocytes and 
fibroblasts in humans [95].     
Mutations in MATN3 gene were found to be associated with autosomal dominant 
forms of multiple epiphyseal dysplasia (MED) and mutations in MATN1 have been 
associated with osteoarthritis and relapsing polychondritis.  MATN2 and MATN4, to date, 
have not been associated with any disease [92,96].  Knock-out mice lacking Matn2 have 
been shown to develop without any obvious abnormalities [97].  Few disorders, including 
Klippel-Fiel syndrome with laryngeal malformations and Cohen syndrome (which consists 
of facial, oral, ocular, and limb deformities, and well as intellectual disability), have been 
linked to the 8q22 position [93].  MATN2, however, has not been identified as a candidate 
gene  in these syndromes [93].   
Despite the lack of obvious craniofacial phenotype in Matn2 knock-out mice, 
interactions of ECM components, growth factors, and embryonic tissues are known to be 
involved in the normal development of cranial priomordia and orofacial structures [98,99] 
and alterations in the ECM components could potentially lead to NSCLP.  
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Solute carrier family 25, member 32 and Folate metabolism 
Solute carrier family 25, member 32 (SLC25A32) gene, also called Mitochondrial 
Folate Transporter (MTF), is located on chromosome 8q21.2.   SLC25A32 consists of 7 
exons and encodes a 315 amino-acid protein transporter which shuttles folates from the 
cytoplasm into the mitochondria [100].  The protein consists of six transmembrane domains: 
three loops facing the mitochondrial matrix and three repeats of an energy transfer sequence 
[100].  The protein does not contain an ATP-binding motif and probably functions as an 
ATP-independent transporter [100].   
Solute carriers are comprised of 43 identified families which control the movement 
of various substances across the cell membrane [101].  Members of the solute carrier family 
25 (SLC25) are known to transfer a variety of substances across the mitochondrial 
membrane, and are therefore referred to as mitochondrial solute carriers [102].  The 
SLC25A32 protein is shown to transport folate across the mitochondrial membrane [100].   
Folate metabolism is a complex process consisting of multiple genes and pathways.  
Folate is absorbed from the environment, transported across the cell membrane, and 
compartmentalized between the mitochondria and the cell cytoplasm before it is transported 
into the mitochondria [103].  The transport of folate into the mitochondria involves various 
transporters and carriers, including the SLC25A32 transporter [100,103].   
The importance of folate in prevention of birth defects has been investigated since 
folate fortification reduced the occurrence of spina bifida, an open neural tube defect 
(ONTD), by approximately 70% [104].  Because ONTDs and NSCLP both develop from 
migrating neural crest cells, studies have been performed to assess the role of folic acid in 
NSCLP in hopes to validate the hypothesis that folic acid deficiency may also contribute to 
17 
 
NSCLP [105,106].  Observational studies of folic acid supplementation and the recurrence 
of NSCLP have not reliably shown the same decrease as with ONTD.   A few meta-analysis 
studies, however, showed decreases of 18-23% in the risk of NSCLP with supplementation 
of folic acid and/or multivitamins during pregnancy [107,108].   Studies also suggest that 
variations in the folate pathway genes may contribute to NSCLP [105].  Disturbances in the 
folate transport, therefore, may also contribute to NSCLP.       
 
Significance of this study 
NSCLP is a common birth defect caused by both genetic and environmental factors.  
Despite decades of research, genetic contributions to NSCLP have yet to be explained, and 
there remains the need to identify candidate genes.  The goal of this project is to further 
elucidate the genetic etiology of NSCLP by sequencing the coding and 5’ and 3’ UTR 
regions of three biologically relevant candidate genes, FZD6, MATN2, and SLC25A32, 
previously identified in a genome wide scan in a large multiplex African-American family.  
This family is unique because NSCLP has a low prevalence in the African American 
population yet there are numerous affected individuals in multiple generations.   Sequence 
variants in any of these three genes may disrupt the highly regulated craniofacial 
development and give rise to NSCLP.   Identification of new genes for NSCLP would not 
only benefit in diagnosis, prevention, and counseling for this birth defect, but may help in 
understanding the developmental pathways involved in craniofacial morphogenesis.   
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MATERIALS AND METHODS 
IRB Approval 
This study was approved by the Committee for the Protection of Human Subjects at 
the University of Texas Health Science Center at Houston (HSC-MS-03-090 and HSC-MS-
11-0336). 
Family  
The focus of this study is an African American NSCLP family with 11 affected 
individuals, 7 of whom were available for evaluation (Fig. 2).  All family members were 
evaluated by one author (JTH).  No other anomalies or lip pits were present in any family 
members.  DNA samples from these 7 individuals and 13 connecting or related unaffected 
family members were subjected to a previously described 6K Illumina IVb genome scan and 
linkage analysis [65].  A maximum multipoint LOD score of 3.0 can be obtained for this 
family.   
Sequencing 
The genomic structure of FZD6, MATN2, and SLC25A32 was determined using the 
NCBI GenBank (www.ncbi.nlm.nih.gov).  Forward and reverse primers were designed to 
capture the sequence of each exon and approximately 50-100 bps upstream and downstream 
of the intron/exon junction, as well as the complete 5’ and 3’ untranslated regions (UTRs) 
for all three isoforms of FZD6, two isoforms of MATN2, and SLC25A32 (Supplemental 
Tables 1-3).  DNA samples from two affected family members (Fig 2: III-15 and IV-2) were 
sequenced for each gene.  These individuals were chosen from the opposite sides of the 
family since they are less likely to share common familial variants.  After initial data 
analysis, 24 additional family members (5 affected and 19 unaffected) were sequenced for 
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rs138557689 using FZD6 primer set E1C (Supplementary Table 1). Standard PCR 
amplification conditions were used and the annealing temperatures for each primer set are 
shown in the Supplemental Tables 1-3.  Amplified PCR product was purified according to 
manufacturer’s protocol (Qiagen, Valencia, CA).  Sequencing results were compared to 
consensus sequences obtained from NCBI public database and analyzed using Sequencer 
v4.9 (Gene Codes, Ann Arbor, MI).   
Variant Analysis 
Sequence variants were identified using dbSNP 
(www.ncbi.nlm.nih.gov/projects/SNP).  Only sequence changes shared by both affected 
individuals (Fig 2: III-15 and IV-2) were considered.  SNPs identified in the potential 
regulatory regions, 5’ UTR and the first two introns of the gene, were assessed for their 
effect on DNA binding using three online in silico analyses: Alibaba2, Patch, and 
Transcription Element Search Software (TESS) [109,110,111].  SNPs identified in the 
3’UTR region were assessed for their effect on microRNA binding sites using 
microRNAMap and miRBAse databases [112,113].  SNPs identified in the coding region 
were analyzed using PolyPhen and SIFT [114,115].  
Species Conservation Analysis 
SNPs were assessed for evolutionary conservation using the UCSC Genome Browser 
Multiz Alignments of 46 Vertebrates track (www.genome.ucsc.edu/cgi-bin/hgGateway) and 
the ECR Browser tool (http://ecrbrowser.dcode.org).   SNPs were further assessed using the 
genomic evolutionary rate profiling (GERP) track within the UCSC browser to estimate the 
evolutionary constraint rates for individual nucleotide positions [116].  GERP scores are 
positive in constrained regions and negative in neutral DNA [116]. 
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Electrophoretic mobility shift assay (EMSA)  
EMSA was used to evaluate whether an ancestral or alternate allele in the SNP of 
interest altered DNA binding.  20-mer oligonucleotide sequences were hybridized 
incorporating either the ancestral or alternate allele (Integrated DNA Technologies, 
Coralville, IA) and labeled with P
32
 dCTP (40,000cpm).  The binding reaction was carried 
out in 20 uL binding buffer mix (1M Tris (pH 7.5), 1M KCl, 80% glycerol, 10% NP-40, 
0.5M EDTA, 100 mM PMSF, 1M DTT and H2O), containing 1 uL poly dGdC and 1 uL 
Cos7 cell nuclear extract, and was incubated on ice for 20 mins.  The sample was incubated 
with the radiolabeled probes for 20 mins at room temperature.  The complexes were 
resolved on a 5% polyacrylamide gel at 150V for 3hrs in TBE buffer.  Gels were dried and 
exposed at -80° C for 48 hrs.  Negative controls were run with cold oligonucleotides using 
the labeled probes and binding buffer without the nuclear extract. 
Genotyping of NSCLP Probands and Unaffected Controls 
A custom TaqMan Genotyping Assay (Applied Biosystems, Foster City, CA) was 
designed to genotype rs138557689 using our standard protocol and was detected on ABI 
Viia7 RUO Machine (Applied Biosystems, Foster City, CA).  A total of 579 controls and 
836 NSCLP probands were genotyped.  Allele calls were determined using the Viia7 
Software (ABI) and the allele call rate was greater than 98%.  
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RESULTS 
Sequencing of the coding and 5’ and 3’ UTR regions for FZD6, MATN2, and 
SLC25A32 identified three sequence variants in III-15 and IV-2 (Fig. 4).  One sequence 
change, a homozygous deletion of nucleotide T (c.*164delT), was identified in the 3’UTR 
of SLC25A32.  This sequence variation is listed in dbSNP as rs11345830, but the frequency 
in the general population was not available.  However, this homozygous deletion is highly 
conserved among primates, is not predicted to affect microRNA binding sites, and was 
therefore excluded from further analysis.  One variant, rs113199627 was identified in the 
5’UTR of MATN2.  This is a common variant in the population (MAF=14.5%) and was also 
excluded from further analysis. 
A single base pair c.-153+432A>C change in FZD6 was present in both individuals 
(Fig. 4).  Rs138557689, a SNP in intron 1, is located 681bps upstream of the start site.   
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Based on the availability of DNA samples, 24 additional relatives were sequenced for the 
same variant.  The C allele was found to segregate with the cleft phenotype where 100% of 
the affected individuals had the CA genotype (Fig 4: II-9, III-2, III-15, III-17, IV-2, IV-6, 
IV-8).  The C allele was transmitted by 4 unaffected individuals (Fig. 4: I-3, II-13, III-4, III-
11) and there were 5 other unaffected family members with the CA genotype (Fig. 4: II-12, 
III-13, IV-5, IV-10, IV-12).  The CA genotype was present in 60% of the unaffected family 
members.  There were no affected individuals, however, with the AA genotype.    
Despite being submitted by the 1000 Genomes project and listed in NCBI, frequency 
data on rs138557689 variant was not available.  To assess the frequency of this allele, we 
genotyped 579 controls of Non-Hispanic White (NHW), Hispanic, and African American 
ethnicity, and found the C allele in 3 individuals (1 NHW and 2 African Americans) who 
were heterozygous.  No homozygous individuals for the C allele were found.   The 
frequency of the C allele was 0.8% in the African American, 0.3% in NHW, and 0% in 
Hispanic controls (Table 2A).   We then genotyped 836 probands from our NSCLP dataset 
and found the C allele in 
two African American 
individuals, who were both 
heterozygous. This 
includes one African 
American proband from 
the family described here.  
The C allele was not found 
in the NHW and Hispanic 
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NSCLP probands.  The frequency of the C allele in the NSCLP dataset was 1.2% for the 
African Americans and 0% for the NHW and Hispanics (Table 2B).  
 To assess whether this SNP was in a conserved region, we compared the sequence 
in different species.  The ancestral A allele of rs138557680 showed conservation in chimps, 
rhesus monkeys, gorillas, marmoset, mouse lemur, and opossum while the alternate C allele 
was only conserved in elephants and armadillos (Fig. 5).  These results suggest that C is a 
rare variant.  The position of the rs138557689 variant showed moderate evolutionary 
constraint (GERP score=-2.98).  This suggests that the A allele is moderately conserved at 
this location and that nucleotide changes at this position are tolerated and not selected 
against through evolution. 
 
24 
 
In silico analyses predicted that the alternate C allele alters DNA binding.  The 
ancestral allele was predicted to create a C/EB alpha transcription factor binding site by 
Patch.  The alternate allele was predicted to create a Sp1 site by AliBaba2, and NF-1/L 
binding site by Patch and NIP and NF-1/L binding sites by TESS.  EMSA analysis was used 
to determine whether a DNA binding site was present with either allele.  As shown in Fig. 6, 
there were two bands present for the probe containing the C allele but not for the A allele.  
These results indicate that the C allele creates new DNA binding sites. 
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DISCUSSION 
We identified a potentially functional variant, rs138557689, in intron 1 of FZD6 
gene segregating with NSCLP phenotype in a large African American family.  In silico 
analysis suggested and EMSA results showed that the alternate C allele creates transcription 
binding sites.  Additionally, the ancestral A allele is highly conserved in primates and 
moderately conserved in other vertebrates, suggesting that it may have important functional 
significance in the regulation of FZD6.  While the CA genotype for the rs138557689 variant 
appears to contribute to the development of NSCLP in this family, analyses are underway to 
assess how the variant affects gene expression. 
The rs138557689/C allele is rare in the general population and was found in less than 
1% of NHW and African American controls.  The C allele was also rare in the NSCLP 
probands being identified in only two of 1672 African American chromosomes.  Even 
though there appears to be an enrichment for the C allele in the African American 
population in our data set, there was no significant difference in the C allele frequency 
between the African American controls and NSLCP probands (p-value=1.0, Fisher exact 
test).  Based on this information the variant does not appear to be relevant at the population 
level.   However, the large number of individuals with the C allele in the African American 
family suggests that the rare rs138557689/C genotype may act as a predisposing risk factor 
for NSCLP when superimposed on the genetic background present in this family.  The 
presence of the C allele in the unaffected family members as well as controls suggests that a 
person must have a specific combination of variants in one or multiple genes to exhibit the 
phenotype.  This is consistent with the multifactorial model and is supported by the observed 
reduced penetrance in this African American family.  Our results also suggest that different 
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ethnic-specific genetic risk profiles may contribute to NSCLP, and therefore the underlying 
disease mechanisms may also be different between ethnic groups.  This is consistent with 
the observed differences in prevalence of NSCLP among different populations and the 
observed genetic heterogeneity that characterizes this complex disorder.  Ethnic-specific 
differences warrant further studies. 
Variants in noncoding regions that modify transcription and expression have 
increasingly been implicated in complex diseases because they perturb transcription by 
creating or removing binding sites for specific transcription factors [21,117,118].  We found 
that the presence of the rs138557689/C allele creates DNA binding sites that could 
potentially repress or enhance the expression of FZD6.  Because the development of facial 
structures is a highly regulated process that relies on crosstalk and convergence of different 
developmental pathways, alterations in the expression of FZD6 could affect the cascade of 
molecular events that the gene is involved in.   
While the exact function of FZD6 in human craniofacial development is not well 
defined, FZD6 is diffusely expressed in the craniofacial mesenchyme of zebrafish and chick 
suggesting that it plays a role during craniofacial development [119,120].  FZD6 is part of 
the Frizzled family of genes which encode a group of G-coupled receptors critical for 
initiation of WNT signaling [66,67].  WNT signaling is a highly controlled cellular pathway 
that regulates multiple functions during development through both canonical/β-catenin and 
noncanonical signal transduction [76,77].  Importantly, WNT signaling has been shown to 
play a role in craniofacial development, including regional specification in the vertebrate 
face, neural crest induction and differentiation, and mid-face development and upper lip 
fusion in mice [26,80,81,82,83,84,85,121].  Craniofacial abnormalities, including orofacial 
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clefts, are found in WNT knock-out mice and zebrafish, while mutations in WNT3 cause 
tetra-amelia with CLP in humans [86,87,122].  Additionally, associations between WNTs 
(WNT3, WNT3A, WNT5A, WNT7A, WNT8A, WNT9B and WNT11) and NSCLP have been 
found, with strongest associations seen in WNT3 and WNT3A [87,88,89,90,123].  Unlike the 
other Frizzleds, FZD6 represses canonical WNT signaling through the noncanonical 
Ca2+/CaMKII pathway by down-regulating TCF/LEF binding activity and subsequent 
transcription of WNT target genes (Fig. 7) [70].   
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An increase in the expression of FZD6 may further repress canonical WNT signaling crucial 
for normal craniofacial development while a decrease in FZD6 expression may cause a loss 
of negative regulation of the WNT pathway.  Negative regulation of the WNT pathway is 
equally important in craniofacial development since mice that are deficient in the Dkk1 gene 
(another negative regulator of the WNT pathway) lack craniofacial structures [124]. 
FZD6 has also been shown to mediate the non-canonical planar cell polarity 
(WNT/PCP) pathway in mice (Fig. 7) [72,73,125].  The WNT/PCP pathway controls the 
polarity and orientation of the migrating neural crest cells [81,126].  During normal 
craniofacial development NCCs migrate from the neural folds to fill the facial prominences 
with mesenchyme and contribute to the formation of the nose and upper lip 
[20,26,28,127,128].  Defects in NCC formation, induction, differentiation, or migration can 
result in craniofacial abnormalities [129,130,131,132].  Therefore, a decrease in FZD6 
expression may perturb the WNT/PCP pathway and alter neural cell migration or 
mesenchymal planar cell polarity in craniofacial structures and may potentially lead to 
NSCLP.   
In summary, we report that a rare genetic variant, rs138557689, which alters DNA 
binding in FZD6, may act as a predisposing risk factor for NSCLP in a large African 
American family with 11 cases of NSCLP segregating in 3 generations.  The alteration in 
FZD6 gene regulation may perturb highly controlled biological pathways, in particular the 
WNT pathway, therefore focusing on the genes within the WNT pathway and their 
interaction with FZD6 may provide further insight into the genetic etiology of NSCLP.  
Assessing the affected and unaffected family members who have the CA genotype for the 
presence of other variants in NSCLP susceptibility genes may delineate the underlying 
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genetic risk profile contributing to development of NSCLP in this family.  This outcome 
would not only improve genetic counseling for this family but may improve the 
understanding of the biological mechanisms linking FZD6 to NSCLP.   
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APPENDIX 
 
Supplementary Table 1.  FZD6 Primers 
Name Forward Reverse Length (bp) Tm(⁰C) 
E1A CACTGCTACCTGAGCATCCA GGA AGC CAC CTC CAC CTT  318 65.1 
E1B AGA GCC AGC GCC AAG AGC TTC A AGG GTG TAG TGC TGC CGT CGA AA   874 65.1 
E1C GGG AAC CGG CTC TGA AAG GCG  CCT TAA TAA GCT TTC CAA CAG GGG CCC  466 69.4 
E1D CTA GTT GGC CTT ACG AAA ATC GAG  GAC CCA GGA CTC ATT TTC AGG  514 60.2 
E2 CAAATGTTGCTGATACACCCTC CACAACTTGAAGAAATCGGCTC 473 54.3 
E3 GAGTTCATAAGTCTGATAGAGGG CTGTAAGTTCCCTGAGAGCAAG 544 54.3 
E4A CCCCATTAACAGCCACAAGTTTT CGCCTAGCAAAAATCCAATGAAG 593 54.3 
E4B GCAACTCTGTTCACATTCCTTAC GTACAAAGTAGCGAGAAGCATCC 481 54.3 
E4C GCAGTGTGGTTTCATGCTGTTG GGCTCTTGTATTTTCTCACCTG 538 54.3 
E5 GATAAAAAATGTGTTGCACTTAGAGC GATAAAAAATGTGTTGCACTTAGAGC 486 54.3 
E6A CTGACAAAAGCAACTTAGAGTG CCTCTCTCATTGATGTTTCTGG 472 54.3 
E6C GGTCATTTCCAAATCCATGGG CAAACTTCCTTGGGGTAAGAG 427 54.3 
E7A GATAAAGGTGGACACTGGTTAG GAAGATTCCTCTAACTCTGTCC 530 54.3 
E7B GCATTGCCTACTGTTATACTGG GGACACTCTTTGAGTAAGCACC  592 54.3 
E7C CCCACTTATTGATACCTTACCATC CAAAAGCATCAGAAAATCTTGCCC 576 54.3 
E7D GCCAATCAAATGGAAAAAAGGTAG GCATTCTCCTTCAAGGTTAAAAAG  450 54.3 
E=Exon 
*Betaine was added to primer E1B during the PCR reaction. 
*DMSO and magnesium chloride were added to primer E1C during the PCR reaction. 
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Supplementary Table 2.  MATN2 Primers 
Name Forward Reverse Length 
(bp) 
Tm(⁰C) 
E1A GCT ACT CTG AGG CAG GAG AAT GG GGC TAA TTG ATG ACA AGC GCC AAG 572 63.5 
E1B GAC TTT CCC TGC TCC CTC GGG GTA GG C CGG GCG GAA GGA GGG GTG TCC 538 65.1 
E1C GGGAGCGCTCTGGGATGGGAC CCT GTC CTC GGA GGG GTC GAA G 374 60.2 
E1D CAT CCCCGC GTC AGT GGG TGC GAG GAC GGA GCC CCA GCT TCT 499 63.1 
E2 CGGCATTTTGAGTGCAAGTGG CCAGCACATCCAACAAGGAC 417 63.5 
E3A GTAGAGACAGGGTTTTACAGTG CCTCTGCTTCTGAGAATGCT 465 63.5 
E3B CGTGCTGTCAAGAGGATGCG CCTATTGCCAGCACAGTACCTG 459 63.5 
E4 CTGCCCAGAGGAGAGAGTAG GGGATGATAACTGGGGTGGG 342 60.2 
E5 GTTACTTTGGTGAGGGCTCTG CTGAGCACTTTGTGGAAACCC 352 63.5 
E6 GCCCTCATCCTACCATTCCC GTTGAGATACAGTGGTCTATGGTC 383 63.5 
E7 CCCCTTCATGGTGTGACTC GCTTAAGATTTGCACGGAAAGG 338 60.2 
E8 GAATGATCCGTCCCGGCTTG GACCATCAGGAAACCCGGTG 375 63.5 
E9 GACACCTTCCCTGTGGCTTG GACACCTTCCCTGTGGCTTG 305 63.5 
E10 GCATGCCTTCGAGGGAGGGC GGCCCAGCAAAGCCTGGAGAC 315 63.5 
E11 GGCCCAGCAAAGCCTGGAGAC CCATTTTCTCTTTCAGGGTCC 400 60.2 
E12 CCATGGACCACTGAGCTCAGG GAGCACCCAAGGCAGGAACTG 379 63.5 
E13 CCCCATCCTGAGTATGAGAC GCAGTTAAGCCCTCTCTTCC 440 63.5 
E14 GGTTCCCCAAAGTGGTTATGCC CTGTACACTCAAAGAAGCTTACCC 625 63.5 
E15 GTTGGCATGGACTCTTCAAATC GCTGAAGCATGAGAATCACTTG 446 63.5 
E16 GCTTTTTTGAATCTTTGGTGTTACC GTAAATGTTAACTATCTTTTTGAGGG 372 63.5 
E17 CCAAGTGCTAGGAATACCAAG CTATTTCCTACTTCCTTCTTTCC 338 56.2 
E18 GGTATTTACTGGATCTGGCTGC CTTGCCCTTGCCTCTCAAAC 425 63.5 
E19A GAG TTC TAC AAA TTT ACA AGT CAG 
GG 
CA AAT GAG ATT GCA CAC TAA GGC 542 56.2 
E19B GTGAGAATGAATAAGCTATGCAAG CCACATCCTTACCAACACTTG 562 62 
E19C GAG AAA TGG CCA ACA TGC CTA TGA 
AAA AAA TGC TG 
CTA CAG GCA CCC ACT ACC ACA CCC G 595 68.2 
E=Exon 
DMSO and magnesium chloride were added to primer E2 during the PCR reaction. 
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Supplementary Table 3.  SLC25A32 Primers 
Name Forward Reverse Length (bp) Tm(⁰C) 
E1A CAT CTC GGT TGC TCT TCC GGC CGC CCC TTG TGA GCG CAA C 431 67 
E1B CCC CTC CAT CGC GCT TTC CG CAG GTT AGC CAA CGC GGA CAG 513 67 
E2 CGG GAC TCT GAC ACA AAA ATG GCC ATT TTG TTC TTC CTG ATC C 519 62 
E3 GCA AAC CAC TTC CAG CAA ATT C CTG AGG CAG GAT TAT CGC TTG 530 58.3 
E4 CCT TTT GAC CCT AAG ACT GTG C GAT ACA TCC TAT GTT AAT GGG GAC 537 58.3 
E5 GTG CTG TAA TGA GAG AGA AGA G GAC ATT TGT GTG GCT TCA 374 58.3 
E6 GAT GAG TAC TGG CTC TGC CA CGT AAT AAC TGG GAA AGC AGG 473 58.3 
E7A GAC TGC TGC TTG CTC CAT GCC GGC AGC CAT TTC AGG CAG AGG 454 58.3 
E7B GAA GCC AGA GAA CTG CTA AGT C CGA CAA AGC AAG ACT CCA TCT C 404 62 
E7C GTG AGC TTA CTT GCC TGG ATT GC CGC TAG GTA GTG CAT CCC AAC TG 543 62 
E7D GGATGGTCTCAATCTCCTGAC CAA CCT GAA TTT GAG AAA CCA ATG AAG 564 58.3 
E7E GTTGACAAGGTAAATGGAAATGAG GTT CAC TTT TTC CGT GTG GGG 517 58.3 
E7F GCT GTT GCA CTA CCA TCT ATT TG CTC AGT GCT TGG TGA CGT AC 556 52 
E=Exon 
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